While amyloid has paved the way for clinical applications of PET imaging for neurotherapeutic development in AD, the radiotracer TauvidTM (a.k.a. [18F]flortaucipir, [18F]AV-1451, [18F]T807) was approved by the FDA for clinical imaging of aggregated tau in 2020 (Fig. 9A). This evidence concerns the gene MAPT and Alzheimer disease.